Related Experiment Video
Updated: Feb 16, 2026

Determining the Optimal Inhibitory Frequency for Cancerous Cells Using Tumor Treating Fields TTFields
Published on: May 4, 2017
Clinical Outcomes in Patients With Gram-Negative Infections Treated With Optimized Dosing Cefepime Over Various
Jerry Altshuler1, David J Guervil2, Charles D Ericsson3
11 Pharmacy Department, Mount Sinai Beth Israel, New York, NY, USA.
Background:
The Clinical and Laboratory Standards Institute (CLSI) revised cefepime interpretive criteria, introducing the susceptible dose-dependent category for Enterobacteriaceae with a minimum inhibitory concentration (MIC) of 4 to 8 μg/mL in 2014. Limited clinical data support these new categories. This study compares outcomes of patients treated with standard and high-dose cefepime across various MICs.
Methods:
We retrospectively reviewed cases of pneumonia or bacteremia caused by gram-negative organisms treated with adequate doses of cefepime for ≥48 hours. Outcomes were compared for MICs of ≤2 (low), 4 (medium), and 8 μg/mL (high). The primary end point was clinical failure, the secondary end point was microbiological failure.
Results:
Ninety cases met the inclusion criteria: 46, 25, and 19 patients with low, medium, or high MIC, respectively. Multivariate logistic regression revealed that the medium (odds ratio [OR]: 9.13, P < .01) and high (OR: 6.79, P = .01) MIC groups had increased clinical failure.
Conclusion:
Cefepime therapy, even at CLSI-recommended doses, had an increased risk of clinical failure for gram-negative pathogens with MICs of 4 or 8 μg/mL. This finding suggests that higher dosing regimens (2 g every 8 hours or 1 g every 6 hours) may be necessary to treat serious gram-negative infections with elevated MICs.
Insights
Cefepime treatment failure increased for gram-negative infections with minimum inhibitory concentrations (MICs) of 4-8 μg/mL. Higher cefepime doses may be needed for these elevated MICs, challenging current guidelines.
Area of Science:
- Infectious Diseases
- Pharmacology
- Clinical Microbiology
Background:
- Clinical and Laboratory Standards Institute (CLSI) updated cefepime susceptibility criteria in 2014.
- New criteria include a susceptible dose-dependent category for Enterobacteriaceae with minimum inhibitory concentrations (MICs) of 4-8 μg/mL.
- Limited clinical data exist to support these revised cefepime interpretive criteria.
Purpose of the Study:
- To compare clinical outcomes in patients treated with standard versus high-dose cefepime.
- To evaluate cefepime efficacy across different MICs for gram-negative organisms.
- To assess the impact of revised CLSI cefepime breakpoints on treatment outcomes.
Main Methods:
- Retrospective review of 90 patients with pneumonia or bacteremia caused by gram-negative organisms.
- Patients received adequate cefepime doses for ≥48 hours.
- Outcomes analyzed based on cefepime MICs: ≤2 μg/mL (low), 4 μg/mL (medium), and 8 μg/mL (high).
Main Results:
- Multivariate analysis showed increased clinical failure in patients with medium (OR: 9.13) and high (OR: 6.79) MICs.
- 46 patients had low MICs, 25 had medium MICs, and 19 had high MICs.
- Both medium and high MIC groups demonstrated statistically significant higher rates of clinical failure.
Conclusions:
- Cefepime therapy, even at standard doses, is associated with higher clinical failure risk for gram-negative pathogens with MICs of 4 or 8 μg/mL.
- Current CLSI-recommended doses may be insufficient for infections with elevated cefepime MICs.
- Higher cefepime dosing regimens (e.g., 2g q8h or 1g q6h) might be required for serious gram-negative infections with higher MICs.
More Related Videos
06:49Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians
Published on: March 14, 2014
13:29Rapid Identification of Gram Negative Bacteria from Blood Culture Broth Using MALDI-TOF Mass Spectrometry
Published on: May 28, 2014
Related Concept Videos
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations
Gram-negative Bacterial Protein Secretion Systems
Drug Dosing: Geriatric Patients
Drug Dosing: Obese Patients
Endocarditis II: Clinical Features of Infective Endocarditis
Drug Dosing in Renal Diseases: Measurement of Serum Creatinine Concentration and Clearance